Fialová L, Svarcová J, Bartos A, Malbohan I. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol (Praha). 2012 May 8. [Epub ahead of print]
Antibodies
have different avidities that can be evaluated using modified
enzyme-linked immunosorbent assay (ELISA) techniques. We determined
levels and avidities of antibodies to light (NFL) and medium (NFM)
subunits of neurofilaments and tau protein in serum and cerebrospinal
fluid (CSF) from 26 MSers and anti-tau antibody levels and their
avidities in 20 multiple sclerosis (MS) patients and 20 age- and sex-matched controls.
The avidities of
anti-neurocytoskeletal antibodies were higher in the CSF than those in
serum (anti-NFL, p < 0.0001; anti-tau, p < 0.01; anti-NFM, n.s.).
There was no relationship between avidities in serum and CSF for
individual anti-neurocytoskeletal antibodies. We did not observe the
relationship among the avidities of various anti-neurocytoskeletal
antibodies. The avidities of anti-tau antibodies in the CSF were
significantly higher in the MS patients than those in the controls
(p < 0.0001). Avidity determination of
anti-neurocytoskeletal antibodies could contribute to the evaluation of
the immunological status of patients.
The binding strength of antibodies directed against internal nerve proteins were looked at in MS and were found to be higher in the cerebrospinal fluid that in the blood. This could be related to the likelihood that more protein is concentrated in the cerbrospinal fluid, compared to the blood as reflects the proximity to the nerve damage, which would not be occurring in healthy people.
No comments:
Post a Comment